BVF INC/IL - Q4 2021 holdings

$2.76 Billion is the total value of BVF INC/IL's 83 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .

 Value Shares↓ Weighting
MRUS NewMERUS N V$131,495,0004,135,071
+100.0%
4.77%
NewEQRX INC$53,603,0007,859,670
+100.0%
1.95%
RLMD NewRELMADA THERAPEUTICS INC$37,116,0001,647,400
+100.0%
1.35%
KDNY NewCHINOOK THERAPEUTICS INC$29,358,0001,800,000
+100.0%
1.07%
CTMX NewCYTOMX THERAPEUTICS INC$25,130,0005,803,700
+100.0%
0.91%
NewPYXIS ONCOLOGY INC$19,651,0001,791,351
+100.0%
0.71%
CNCE NewCONCERT PHARMACEUTICALS INC$7,097,0002,253,000
+100.0%
0.26%
CNTA NewCENTESSA PHARMACEUTICALS PLCsponsored ads$5,118,000454,545
+100.0%
0.19%
GBIO NewGENERATION BIO CO$1,338,000189,050
+100.0%
0.05%
NewBIONOMICS LIMITEDads$1,016,00080,971
+100.0%
0.04%
VYGR NewVOYAGER THERAPEUTICS INC$60,00022,200
+100.0%
0.00%
Other managers

Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):

Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
XENON PHARMACEUTICALS INC36Q3 20234.7%
PIERIS PHARMACEUTICALS INC30Q3 20232.8%
CYTOKINETICS INC29Q4 202011.8%
INFINITY PHARMACEUTICALS INC29Q2 20234.3%
XOMA CORP DEL28Q3 20237.3%
ARQULE INC27Q4 20194.8%
CHEMOCENTRYX INC26Q3 201913.8%
CYTOMX THERAPEUTICS INC26Q3 20235.3%
CORVUS PHARMACEUTICALS INC26Q3 20232.3%
ARRAY BIOPHARMA INC25Q2 201914.5%

View BVF INC/IL's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-14
42024-01-29
32024-01-26
42024-01-09
42023-12-20
42023-11-17
13F-HR2023-11-14
32023-11-13
32023-11-06
42023-11-06

View BVF INC/IL's complete filings history.

Compare quarters

Export BVF INC/IL's holdings